Articles tagged with: Kaletra
Results from two new studies indicate that Kaletra plus Isentress may be as safe and effective as standard treatment regimens for people with HIV. One study was conducted in treatment-experienced patients and the other in people who had not previously taken antiretrovirals.
The results were presented this week at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2011).
Standard antiretroviral therapy includes two nucleoside reverse transcriptase inhibitors (NRTIs) plus at least one additional antiretroviral from a different class. However, some people are unable to tolerate …
Abbott Laboratories To Develop New Combination Antiretroviral Pill – Abbott Laboratories announced last week that it will be developing a new combination antiretroviral pill consisting of Kaletra (lopinavir/ritonavir) and GlaxoSmithKline’s Epivir (lamivudine). According to Abbott, the proposed combination would reduce the number of pills patients have to take and would be more cost-effective than purchasing the medications separately. The combination pill would still need to be taken with at least one other antiretroviral. Abbott is also working on a powder (rather than liquid) formulation of Norvir (ritonavir), which could be added to food or drinks and may be easier for children to take. For more information, please see the Abbott Laboratories press release.
Gilead Sciences Agrees To License New HIV Drugs To Generic Drug Companies In Developing Countries – Gilead Sciences has signed agreements with several generic drug companies in India that will allow them to produce low-cost versions of the antiretrovirals Viread (tenofovir) and Emtriva (emtricitabine) for developing countries. The agreements will extend to the investigational drugs elvitegravir, cobicistat, and the combination “Quad” pill (cobicistat/elvitegravir/emtricitabine/tenofovir) if the drugs are approved. The agreement makes Gilead the first company to join the Medicines Patent Pool, an effort to bring newer antiretrovirals that are still under patent protection to people in developing nations. However, the agreement has faced criticism from Médecins Sans Frontières (also known as Doctors Without Borders) for excluding certain middle-income countries, such as Thailand and Brazil. For more information, please see the press releases from Gilead Sciences and Médecins Sans Frontières.
AIDSinfo Updates “HIV And Its Treatment” Factsheets – AIDSinfo, a website run by the Department of Health and Human Services (DHHS), has updated its factsheets on “HIV and Its Treatment” to include information from the latest DHHS treatment guidelines for adults and adolescents. The factsheets are intended for people with HIV and their friends or families and include information on current treatment recommendations, HIV testing, transmission prevention, and other topics. For more information, please see the updated factsheets (pdf) or the AIDSinfo website.
Results of a very small Italian study indicate that a half dose of Kaletra may be safe and effective for people with HIV who have not previously been treated with protease inhibitors. The study also found that the lower dose helped lower participants’ high triglyceride levels.
The authors did note that, consistent with results from an earlier study, the participants who started treatment at the lower dose had levels of Kaletra in the blood that were below the “minimum effective concentration,” which is the lowest amount of a drug in …
The results of a recent French study indicate that treating uninfected infants of HIV-positive mothers with Kaletra before and after birth may increase the risk of developing temporary but serious adrenal gland problems compared to treating newborns with zidovudine.
While the majority of infants treated with Kaletra had no symptoms, three premature infants treated with Kaletra experienced life-threatening problems, including extensive heart damage, low levels of sodium in the blood, and high levels of potassium in the blood.
“The association between [Kaletra] and transient adrenal dysfunction in HIV-uninfected newborns suggests …
Tibotec Pharmaceuticals and Gilead Sciences have agreed to develop a new once-daily combination antiretroviral pill that combines the protease inhibitor Prezista with the investigational booster cobicistat.
In addition, the companies are currently in negotiations to develop a second pill combining Prezista, cobicistat, Emtriva, and an investigational new form of Viread called GS 7340.
“We are excited to be able to study and develop Prezista with an alternative boosting agent in a combination product which has the potential to reduce the number of tablets patients take,” said Dr. Johan Van Hoof, …